谌莹莹 1梁锦军 1石少波 1王芳 1谌晶晶 1杨波1
作者信息
摘要
Abstract
Objective To explore the effect on incidence of liver dysfunction, cardiomyopathy, stroke and cancer in patients which long-term applied pravastatin in hyperlipidemia patients. Methods A Meta-analysis of randomized, placebo-controlled trials( RCT ) was performed with a database search of the MEDLINE, EMBASE Pub med, Cochrane Central Register of Controlled Trials ( CENTRAL ), China biological medical literature database, China journal full-text database and Wan-fang data on pravastatin, hyperlipemia, coronary heart disease. Results Totally 15 articles were screened. The results showed that there was no significant differences between patients applied pravastatin and placebo on their liver dysfunction ( OR = 1.03, 95%CI 0.86~ 1. 23, P =0.76), incidence of cardiomyopathy ( OR = 1. 17, 95% CI 0. 84 ~ 1. 63, P=0.35), and incidence of cancer ( OR = 1.06, 95% CI 0. 99 ~ 1. 14, P =0.12), and pravastatin were superior to placebo for decreasing the stroke incidence ( OR = 0. 85, 95% CI 0. 76 ~ 0. 94, P = 0.002 ), pravastatin 20mg lower total deaths ( OR = 0. 76, 95% CI 0. 60 ~0. 90, P = 0.02 ), more obvious than pravastatin 40mg ( OR = 0. 87, 95% CI 0. 72 ~ 1. 06, P =0.17). Conclusion It demonstrated that the pravastatin could decrease the incidence of stroke, and there was no significant side effect on liver function, cardiomyopathy and cancer incidence.关键词
普伐他汀/冠心病/高脂血症/安全性/Meta分析Key words
Pravastatin/ Coronary heart disease/ Hyperlipidaemia/ Safety/ Meta-analysis
